Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
BI 1387446 + ezabenlimab
- Development stage
- Discontinued
- Lead developer
- Boehringer Ingelheim
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Intratumoral, Intravenous
01
Overview
**BI 1387446 + ezabenlimab** is a combination of two experimental immunotherapy drugs developed by Boehringer Ingelheim for the treatment of advanced or metastatic solid tumors. **BI 1387446** is a small molecule STING (Stimulator of Interferon Genes) agonist administered intratumorally, which activates the innate immune response and promotes anti-tumor immunity. **Ezabenlimab** (also known as BI 754091) is a monoclonal antibody checkpoint inhibitor targeting PD-1 (Programmed cell death protein 1), administered intravenously, blocking the PD-1 pathway to enhance T cell activity against cancer cells. The combination was investigated in a completed phase I dose-escalation trial, but development of BI 1387446 in this setting has been discontinued[1][2][3][5].
- Other names
- ezabenlimabBI 754091BI754091BI-754091
02
Targets
PDCD1 (Programmed cell death protein 1 receptor)STING (Stimulator of interferon genes protein)
Beyond the preview
Go deeper on BI 1387446 + ezabenlimab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on BI 1387446 + ezabenlimab.